- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| LYELL IMMUNOPHARMA Aktie jetzt für 0€ handeln | |||||
| Fr | Lyell Immunopharma registers 625,000 shares for resale | 1 | Seeking Alpha | ||
| 26.06. | Lyell Immunopharma, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 24.06. | Lyell Immunopharma price target raised to $10 from $1 at H.C. Wainwright | 1 | Investing.com | ||
| 23.06. | Lyell Immunopharma, Inc: Lyell Immunopharma to Participate in the H.C. Wainwright "HCW@Home" Series | 3 | GlobeNewswire (USA) | ||
| 17.06. | Lyell Immunopharma, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 17.06. | Lyell Immunopharma, Inc: Lyell Immunopharma Announces Positive New Clinical Data Demonstrating High Rates of Durable Complete Responses from the Phase 1/2 Trial of LYL314 for the Treatment of Aggressive Large B-cell Lymphoma | 99 | GlobeNewswire (Europe) | LYL314 demonstrated robust clinical responses, with an 88% overall response rate and a 72% complete response rate in patients treated in the third- or later-line setting (N = 25)71% of patients with... ► Artikel lesen | |
| 10.06. | Lyell Immunopharma strengthens clinical and commercial capabilities with executive appointments | 4 | Seeking Alpha | ||
| 09.06. | Lyell Immunopharma, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 09.06. | Lyell Immunopharma, Inc: Lyell Immunopharma Strengthens Clinical and Commercial Capabilities with Key Board and Executive Appointments | 115 | GlobeNewswire (Europe) | Mark J. Bachleda, PharmD, MBA appointed as independent member of the Board of DirectorsDavid Shook, MD appointed as Chief Medical Officer, Mark Meltz, JD as General Counsel and Corporate Secretary... ► Artikel lesen | |
| 21.05. | Lyell Immunopharma, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 14.05. | Lyell Immunopharma reports Q1 results | 2 | Seeking Alpha | ||
| 13.05. | Lyell Immunopharma, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 13.05. | Lyell Immunopharma, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 13.05. | Lyell Immunopharma, Inc: Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2025 | 222 | GlobeNewswire (Europe) | Presenting new clinical data from Phase 1/2 multi-center clinical trial of LYL314, a next-generation dual-targeting CD19/CD20 CAR T-cell product candidate for the treatment of relapsed and/or refractory... ► Artikel lesen | |
| 15.04. | Lyell Immunopharma gets FDA RMAT status for lymphoma treatment | 1 | Seeking Alpha | ||
| 15.04. | Lyell Immunopharma, Inc: Lyell Immunopharma Receives Regenerative Medicine Advanced Therapy (RMAT) Designation for LYL314 for the Treatment of Relapsed and/or Refractory Large B-Cell Lymphoma | 159 | GlobeNewswire (Europe) | RMAT designation was granted based on promising clinical data from the ongoing Phase 1/2 trial of LYL314 in patients with relapsed and/or refractory large B-cell lymphoma.RMAT designation recognizes... ► Artikel lesen | |
| 01.04. | Lyell Immunopharma, Inc. - 8-K, Current Report | 5 | SEC Filings | ||
| 11.03. | Lyell Immunopharma reports Q4 results | 2 | Seeking Alpha | ||
| 11.03. | Lyell Immunopharma, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 11.03. | Lyell Immunopharma, Inc. - 10-K, Annual Report | 2 | SEC Filings |
1 2 Weiter >>
26 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| MEDIGENE | 0,121 | -8,36 % | PTA-Adhoc: Medigene AG: Ausscheiden des Vorstandsvorsitzenden Dr. Selwyn Ho und Bestellung von Ralph Schäfer als Vorstand | DJ PTA-Adhoc: Medigene AG: Ausscheiden des Vorstandsvorsitzenden Dr. Selwyn Ho und Bestellung von Ralph Schäfer als Vorstand
Veröffentlichung von Insiderinformationen gemäß Artikel 17 MAR
... ► Artikel lesen | |
| AMGEN | 253,65 | 0,00 % | Amgen: Robustes Pharma-Geschäft und Dividende | Die Amgen-Aktie stellt eine attraktive Depotbeimischung für jedes diversifizierte oder Pharma-orientierte Anlegerdepot dar. Die Bewertung ist vergleichsweise günstig, die Aussichten stabil. Und es gibt... ► Artikel lesen | |
| BIOGEN | 107,35 | -0,23 % | Here's What to Expect From Biogen's Next Earnings Report | ||
| PALATIN TECHNOLOGIES | 0,120 | -10,60 % | Palatin Technologies, Inc.: Palatin Announces Positive Preclinical Efficacy Data for Oral MC4R Agonist PL7737 in Animal Model of Obesity | Oral PL7737 monotherapy produced rapid and significant weight loss after just 4 days of treatment
Combination of oral PL7737 and tirzepatide resulted in additive... ► Artikel lesen | |
| BIOXXMED | 0,410 | +32,26 % | EQS-News: bioXXmed AG informiert über die Verzögerung der Veröffentlichung des geprüften Jahresabschlusses 2024 | EQS-News: bioXXmed AG
/ Schlagwort(e): Jahresbericht
bioXXmed AG informiert über die Verzögerung der Veröffentlichung des geprüften Jahresabschlusses 2024
27.06.2025 /... ► Artikel lesen | |
| VIVOSIM LABS | 1,220 | -100,00 % | VivoSim Labs, Inc.: VivoSim Announces Emergence from Stealth Mode To Provide Technologies for FDA Turn Away from Animal Models, $10B+ Market | SAN DIEGO, April 24, 2025 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the "Company") announced that it has emerged from stealth mode to dramatically impact drug discovery and development.... ► Artikel lesen | |
| OCUGEN | 0,920 | +5,31 % | Ocugen, Inc. Announces First Patient Dosed in Phase 2/3 GARDian3 Pivotal Confirmatory Trial for OCU410ST-Novel Modifier Gene Therapy Candidate for Stargardt Disease | MALVERN, Pa., July 18, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that... ► Artikel lesen | |
| SIRONA BIOCHEM | 0,037 | -100,00 % | Sirona Biochem gibt Finanzierung mittels Wandelschuldverschreibung bekannt | Vancouver, British Columbia, 22. April 2025 / IRW-Press / Sirona Biochem Corp. (TSX-V: SBM) (FWB: ZSB) (OTC: SRBCF) ("Sirona" oder das "Unternehmen") gibt eine nicht vermittelte Privatplatzierung... ► Artikel lesen | |
| BIO-GATE | 0,990 | -4,81 % | Bio-Gate beschließt Ausgabe einer Wandelschuldverschreibung unter Ausschluss des Bezugsrechts | Nürnberg (www.anleihencheck.de) - Bio-Gate beschließt Ausgabe einer Wandelschuldverschreibung unter Ausschluss des Bezugsrechts - AnleihenewsVorstand und Aufsichtsrat der Bio-Gate AG (ISIN DE000BGAG981/... ► Artikel lesen | |
| EDITAS MEDICINE | 2,428 | +2,40 % | Editas Medicine, Inc.: Editas Medicine Reports Proprietary Targeted Lipid Nanoparticle Delivery in Non-Human Primates Enables In Vivo HBG1/2 Promoter Editing for Sickle Cell Disease and Beta Thalassemia at the European Hematology ... | Achieved 58% mean editing at five months after a single dose using high efficiency HSC delivery, demonstrating therapeutically relevant editing levels using a clinically validated strategy. Achievement... ► Artikel lesen | |
| DEFENCE THERAPEUTICS | 0,415 | +1,72 % | Defence Therapeutics Inc.: Defence's Accum Technology with ADC and Radiopharmaceutical Programs Target Cancer | Montreal, Quebec--(Newsfile Corp. - July 14, 2025) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a leading biotechnology company specializing in drug... ► Artikel lesen | |
| VAXART | 0,349 | +8,72 % | OTC Markets Group Welcomes Vaxart, Inc. to OTCQX | NEW YORK, July 08, 2025 (GLOBE NEWSWIRE) -- OTC Markets Group Inc. (OTCQX: OTCM), operator of regulated markets for trading 12,000 U.S. and international securities, today announced Vaxart, Inc. (OTCQX:... ► Artikel lesen | |
| BURCON NUTRASCIENCE | 1,836 | 0,00 % | Burcon NutraScience Corporation: Burcon to Showcase Chipotle Black Bean Protein Hummus at 2025 IFT FIRST Annual Event & Expo | Vancouver, British Columbia--(Newsfile Corp. - July 10, 2025) - Burcon NutraScience Corporation (TSX: BU) (OTCQB: BRCNF) ("Burcon" or the "Company"), a global technology leader in plant-based protein... ► Artikel lesen | |
| CELLECTAR BIOSCIENCES | 4,970 | 0,00 % | Cellectar Biosciences, Inc.: Cellectar Biosciences and U.S.-based Nusano Enter Into Multi-Isotope Supply Agreement | Partnership Provides Long-Term Supply of Iodine-125 and Actinium-225 Supports Advancement of Radiotherapeutic Pipeline and Plans to Initiate Phase 1b Clinical Trial of CLR-125 for Triple-Negative... ► Artikel lesen | |
| GALAPAGOS NV | 27,000 | +0,75 % | Galapagos NV: Galapagos Appoints Aaron Cox as Chief Financial Officer | Former Horizon CFO joins Galapagos with deep expertise in international corporate finance, M&A, business development and strategic leadership
Mechelen, Belgium; June 23, 2025, 07:30 CET; regulated... ► Artikel lesen |
LYELL IMMUNOPHARMA INC gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 9,280 Euro und damit -3,13 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu LYELL IMMUNOPHARMA INC finden Sie auf Wallstreet Online.